EX 597
Alternative Names: EX-597; KDS-4103; ORG-231295; URB-597Latest Information Update: 28 Nov 2023
At a glance
- Originator Kadmus Pharmaceuticals; University of California at Irvine
- Developer Exxel Pharma; Unknown
- Class Amides; Anxiolytics; Behavioural disorder therapies; Biphenyl compounds; Carbamates; Cyclohexanes; Small molecules
- Mechanism of Action Fatty acid amide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Post-traumatic stress disorders; Social phobia
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for preclinical development in Post-traumatic-stress-disorders in USA (PO)
- 28 Nov 2023 No recent reports of development identified for preclinical development in Social-phobia in USA (PO)
- 27 Nov 2023 Preclinical trials in Post-traumatic stress disorders in USA (unspecified route) before July 2006 (Exxel Pharma pipeline, November 2023)